Pila Pharma（5KC）株式概要Pila Pharma AB（publish）はスウェーデンで臨床段階のバイオテクノロジー企業として活動している。 詳細5KC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( €7M )収益が 100 万ドル未満 ( SEK1M )すべてのリスクチェックを見る5KC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.148.1k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-27m2m2016201920222025202620282031Revenue SEK 1.3mEarnings SEK 190.7kAdvancedSet Fair ValueView all narrativesPila Pharma AB (publ) 競合他社BiofronteraSymbol: XTRA:B8FKMarket cap: €14.6mTFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mCantourage GroupSymbol: XTRA:HIGHMarket cap: €75.3mMPH Health CareSymbol: DB:93M1Market cap: €110.0m価格と性能株価の高値、安値、推移の概要Pila Pharma過去の株価現在の株価SEK 0.1452週高値SEK 0.4152週安値SEK 0.087ベータ-0.321ヶ月の変化-0.36%3ヶ月変化40.00%1年変化-48.62%3年間の変化-37.22%5年間の変化n/aIPOからの変化-84.44%最新ニュースお知らせ • Mar 20Pila Pharma AB (publ), Annual General Meeting, May 19, 2026Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time.お知らせ • Dec 23Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026お知らせ • Dec 20Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in ObesityPila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity.お知らせ • Oct 29Pila Pharma AB (publ) announced that it has received SEK 30 million in fundingPila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered.お知らせ • Sep 04Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026お知らせ • Mar 28+ 1 more updatePila Pharma AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026Pila Pharma AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026最新情報をもっと見るRecent updatesお知らせ • Mar 20Pila Pharma AB (publ), Annual General Meeting, May 19, 2026Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time.お知らせ • Dec 23Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026お知らせ • Dec 20Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in ObesityPila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity.お知らせ • Oct 29Pila Pharma AB (publ) announced that it has received SEK 30 million in fundingPila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered.お知らせ • Sep 04Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026お知らせ • Mar 28+ 1 more updatePila Pharma AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026Pila Pharma AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026お知らせ • Jan 02+ 2 more updatesPila Pharma AB (publ) to Report Fiscal Year 2024 Results on Mar 27, 2025Pila Pharma AB (publ) announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Mar 27, 2025お知らせ • Dec 19Pila Pharma AB (Publ) Announces Preclinical Preclinical Proof-Of-Concept Achieved in Cardiometabolic DiseasesPILA PHARMA AB (publ) announced the completion of the study of the Research Group of Professor Dick Wagsater, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice. The aim of the preclinical study was to establish a pre-clinical proof-of-concept of that the TRPV1 antagonist XEN-D0501 could decrease Abdominal Aneurysm growth In mice. The headline study results show that XEN-D0501 had a robust decrease in aorta dilatation of more than 50% compared to placebo, which was the goal. It almost completely inhibited aneurysm development in this pre-clinical model, thus, establishing proof-of-concept. Pending a confirmatory study, the data will be published and presented in a scientific outlet. XEN-D0501 is a selective, synthetic potent small molecule TRPV1 antagonist that was in-licensed in 2016. TRPV1 antagonists that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. Prior to in-licensing, XEN-D051 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D051 is well tolerated by in people living with obesity and type 2 diabetes. Further, PP-CT02, demonstrated that XEN-D0701 (administered as 4 mg bidaily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. Furthermore, ANP, a cardiovascular biomarker for heart failure, was highly statistically significantly reduced. During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. Currently, a scientific advice regarding the study design of the next clinical phase 2a trial, PP-CT03, is being prepared and will be followed by a clinical trial submission in the UK. The objective of the study is to identify the maximal tolerable dose of XEN-D051 in people living with obesity and Type 2 diabetes and to evaluate the safety profile following 3 months chronic treatment. In addition to the safety assessment, PP-CT03 will also include sufficient participants that should allow for efficacy readouts on reduction of body weight.お知らせ • Nov 14PILA PHARMA AB (publ) Announces Selection of Clinical Trial Site and Decision to Seek Scientific Advice for Optimized PP-CT03 Study DesignPILA PHARMA AB (publ) announced the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical trial site for the conduct of PP-CT03 as well as the as having decided to seek further scientific advice as first step. On 17 October, PILA PHARMA informed of optimization changes to the trial plan for PP-CT03 plan, due mainly to internal safety concerns of running the trial at a non-hospital site, as well as the decision to conduct at least the initial part at a hospital site. The company has now selected the scientific advisor to PILA PHARMA, Professor Mark Evans, as principal investigator of the study and the Cambridge University Hospital, UK, as the principal trial site of PP-CT03. Furthermore, following discussions with Professor Evans, it has been decided to seek scientific advice with the UK MRHA prior to clinical trial application. The objective is to further strengthen the PP-CT03 study design and increase the opportunity for this study to provide input to a clear development and regulatory plan in diabetes and potentially obesity.Reported Earnings • Aug 28First half 2024 earnings releasedFirst half 2024 results: Revenue: kr683.0k (down 38% from 1H 2023). Net loss: kr4.09m (loss narrowed 42% from 1H 2023).お知らせ • Apr 24Pila Pharma AB (publ) to Report First Half, 2024 Results on Aug 27, 2024Pila Pharma AB (publ) announced that they will report first half, 2024 results on Aug 27, 2024お知らせ • Apr 20+ 1 more updatePila Pharma AB (Publ) Announces Board and Management AppointmentsPila Pharma AB at the Annual General Meeting held on April 18, 2024 announced its founder and Director of the Board, Dorte X. Gram was elected new Chairman of the Board with immediate effect. The newly elected Board of Directors has subsequently appointed Dorte X. Gram as Chief Scientific Officer (CSO) of Pila Pharma AB. Further two new members have been elected to strengthen the Boards financial, strategic and market insight, thus recalibrating the objectives of Pila Pharma AB. Lasse Richter Petersen has been elected Director of the Board due to his extensive background and experience in the international pharmaceutical business including diabetes, and Julie Waras Brogren has been elected Director of the Board due to her extensive experience in developing strategies for advancing pharma assets from development to commercialisation and in finance and investor relations.Reported Earnings • Feb 29Full year 2023 earnings released: kr0.54 loss per share (vs kr1.55 loss in FY 2022)Full year 2023 results: kr0.54 loss per share (improved from kr1.55 loss in FY 2022). Revenue: kr1.46m (down 22% from FY 2022). Net loss: kr9.93m (loss narrowed 63% from FY 2022).お知らせ • Dec 06Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million.Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,385,920 Price\Range: SEK 1.5 Transaction Features: Rights OfferingReported Earnings • Oct 28Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr1.53m (loss narrowed 74% from 3Q 2022).Reported Earnings • Aug 23Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr301.0k (down 54% from 2Q 2022). Net loss: kr3.06m (loss narrowed 53% from 2Q 2022).Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director of the Board Richard Busellato was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 27First quarter 2023 earnings released: kr0.22 loss per share (vs kr0.64 loss in 1Q 2022)First quarter 2023 results: kr0.22 loss per share (improved from kr0.64 loss in 1Q 2022). Revenue: kr796.0k (up 49% from 1Q 2022). Net loss: kr4.04m (loss narrowed 61% from 1Q 2022).Board Change • Feb 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Aug 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Aug 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 02Pila Pharma AB (Publ) Announces the Preclinical Toxicological Three-Month Studies of the Active Substance Xen-D0501 Has BegunPila Pharma AB (publ) announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical trials in humans with up to one month doses with very good safety results, indicating that the molecule is very well tolerated. The new preclinical toxicological studies aims to confirm the safety of the duration of the forthcoming phase 2b study, i.e three months.Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Director Gudmund Korsgard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 26Pila Pharma AB Announces Certification of APIPila Pharma AB announced that the study material to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety studies was outsourced to Almac Group. This production has now been completed as Almac has verified that the final product complies with the specifications and has issued a certificate of analysis. This in turn means that Pila Pharma's development of a new diabetes drug is going according to plan, and that the company can now proceed towards the planned longer preclinical studies that are necessary to be able to carry out a clinical phase 2b study.株主還元5KCDE PharmaceuticalsDE 市場7D-2.8%5.7%2.4%1Y-48.6%25.9%1.2%株主還元を見る業界別リターン: 5KC過去 1 年間で25.9 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: 5KCは、過去 1 年間で1.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 5KC's price volatile compared to industry and market?5KC volatility5KC Average Weekly Movement17.7%Pharmaceuticals Industry Average Movement6.4%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: 5KCの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 5KCの weekly volatility ( 18% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/aGustav Grampilapharma.comPila Pharma AB (publish)はスウェーデンで臨床段階のバイオテクノロジー企業として活動している。同社はTRPV1拮抗薬XEN-D0501を開発し、肥満、糖尿病、心不全を対象としたフェーズ2a試験、紅斑痛、炎症性疼痛、希少疾患を対象としたフェーズ1試験、腹部大動脈瘤、心血管疾患を対象とした前臨床試験を行っている。Pila Pharma AB（publ）は2014年に設立され、スウェーデンのマルメに本社を置いている。もっと見るPila Pharma AB (publ) 基礎のまとめPila Pharma の収益と売上を時価総額と比較するとどうか。5KC 基礎統計学時価総額€6.70m収益（TTM）-€1.57m売上高(TTM)€104.20k64.3xP/Sレシオ-4.3xPER（株価収益率5KC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計5KC 損益計算書（TTM）収益SEK 1.13m売上原価SEK 7.08m売上総利益-SEK 5.96mその他の費用SEK 11.05m収益-SEK 17.00m直近の収益報告Dec 31, 2025次回決算日Aug 27, 2026一株当たり利益（EPS）-0.37グロス・マージン-528.70%純利益率-1,509.00%有利子負債／自己資本比率0%5KC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 01:56終値2026/05/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pila Pharma AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Filip EinarssonRedeye
お知らせ • Mar 20Pila Pharma AB (publ), Annual General Meeting, May 19, 2026Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time.
お知らせ • Dec 23Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026
お知らせ • Dec 20Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in ObesityPila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity.
お知らせ • Oct 29Pila Pharma AB (publ) announced that it has received SEK 30 million in fundingPila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered.
お知らせ • Sep 04Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026
お知らせ • Mar 28+ 1 more updatePila Pharma AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026Pila Pharma AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026
お知らせ • Mar 20Pila Pharma AB (publ), Annual General Meeting, May 19, 2026Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time.
お知らせ • Dec 23Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026
お知らせ • Dec 20Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in ObesityPila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity.
お知らせ • Oct 29Pila Pharma AB (publ) announced that it has received SEK 30 million in fundingPila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered.
お知らせ • Sep 04Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026
お知らせ • Mar 28+ 1 more updatePila Pharma AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026Pila Pharma AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026
お知らせ • Jan 02+ 2 more updatesPila Pharma AB (publ) to Report Fiscal Year 2024 Results on Mar 27, 2025Pila Pharma AB (publ) announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Mar 27, 2025
お知らせ • Dec 19Pila Pharma AB (Publ) Announces Preclinical Preclinical Proof-Of-Concept Achieved in Cardiometabolic DiseasesPILA PHARMA AB (publ) announced the completion of the study of the Research Group of Professor Dick Wagsater, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice. The aim of the preclinical study was to establish a pre-clinical proof-of-concept of that the TRPV1 antagonist XEN-D0501 could decrease Abdominal Aneurysm growth In mice. The headline study results show that XEN-D0501 had a robust decrease in aorta dilatation of more than 50% compared to placebo, which was the goal. It almost completely inhibited aneurysm development in this pre-clinical model, thus, establishing proof-of-concept. Pending a confirmatory study, the data will be published and presented in a scientific outlet. XEN-D0501 is a selective, synthetic potent small molecule TRPV1 antagonist that was in-licensed in 2016. TRPV1 antagonists that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. Prior to in-licensing, XEN-D051 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D051 is well tolerated by in people living with obesity and type 2 diabetes. Further, PP-CT02, demonstrated that XEN-D0701 (administered as 4 mg bidaily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. Furthermore, ANP, a cardiovascular biomarker for heart failure, was highly statistically significantly reduced. During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. Currently, a scientific advice regarding the study design of the next clinical phase 2a trial, PP-CT03, is being prepared and will be followed by a clinical trial submission in the UK. The objective of the study is to identify the maximal tolerable dose of XEN-D051 in people living with obesity and Type 2 diabetes and to evaluate the safety profile following 3 months chronic treatment. In addition to the safety assessment, PP-CT03 will also include sufficient participants that should allow for efficacy readouts on reduction of body weight.
お知らせ • Nov 14PILA PHARMA AB (publ) Announces Selection of Clinical Trial Site and Decision to Seek Scientific Advice for Optimized PP-CT03 Study DesignPILA PHARMA AB (publ) announced the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical trial site for the conduct of PP-CT03 as well as the as having decided to seek further scientific advice as first step. On 17 October, PILA PHARMA informed of optimization changes to the trial plan for PP-CT03 plan, due mainly to internal safety concerns of running the trial at a non-hospital site, as well as the decision to conduct at least the initial part at a hospital site. The company has now selected the scientific advisor to PILA PHARMA, Professor Mark Evans, as principal investigator of the study and the Cambridge University Hospital, UK, as the principal trial site of PP-CT03. Furthermore, following discussions with Professor Evans, it has been decided to seek scientific advice with the UK MRHA prior to clinical trial application. The objective is to further strengthen the PP-CT03 study design and increase the opportunity for this study to provide input to a clear development and regulatory plan in diabetes and potentially obesity.
Reported Earnings • Aug 28First half 2024 earnings releasedFirst half 2024 results: Revenue: kr683.0k (down 38% from 1H 2023). Net loss: kr4.09m (loss narrowed 42% from 1H 2023).
お知らせ • Apr 24Pila Pharma AB (publ) to Report First Half, 2024 Results on Aug 27, 2024Pila Pharma AB (publ) announced that they will report first half, 2024 results on Aug 27, 2024
お知らせ • Apr 20+ 1 more updatePila Pharma AB (Publ) Announces Board and Management AppointmentsPila Pharma AB at the Annual General Meeting held on April 18, 2024 announced its founder and Director of the Board, Dorte X. Gram was elected new Chairman of the Board with immediate effect. The newly elected Board of Directors has subsequently appointed Dorte X. Gram as Chief Scientific Officer (CSO) of Pila Pharma AB. Further two new members have been elected to strengthen the Boards financial, strategic and market insight, thus recalibrating the objectives of Pila Pharma AB. Lasse Richter Petersen has been elected Director of the Board due to his extensive background and experience in the international pharmaceutical business including diabetes, and Julie Waras Brogren has been elected Director of the Board due to her extensive experience in developing strategies for advancing pharma assets from development to commercialisation and in finance and investor relations.
Reported Earnings • Feb 29Full year 2023 earnings released: kr0.54 loss per share (vs kr1.55 loss in FY 2022)Full year 2023 results: kr0.54 loss per share (improved from kr1.55 loss in FY 2022). Revenue: kr1.46m (down 22% from FY 2022). Net loss: kr9.93m (loss narrowed 63% from FY 2022).
お知らせ • Dec 06Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million.Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,385,920 Price\Range: SEK 1.5 Transaction Features: Rights Offering
Reported Earnings • Oct 28Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr1.53m (loss narrowed 74% from 3Q 2022).
Reported Earnings • Aug 23Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr301.0k (down 54% from 2Q 2022). Net loss: kr3.06m (loss narrowed 53% from 2Q 2022).
Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director of the Board Richard Busellato was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 27First quarter 2023 earnings released: kr0.22 loss per share (vs kr0.64 loss in 1Q 2022)First quarter 2023 results: kr0.22 loss per share (improved from kr0.64 loss in 1Q 2022). Revenue: kr796.0k (up 49% from 1Q 2022). Net loss: kr4.04m (loss narrowed 61% from 1Q 2022).
Board Change • Feb 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Aug 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Aug 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 02Pila Pharma AB (Publ) Announces the Preclinical Toxicological Three-Month Studies of the Active Substance Xen-D0501 Has BegunPila Pharma AB (publ) announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical trials in humans with up to one month doses with very good safety results, indicating that the molecule is very well tolerated. The new preclinical toxicological studies aims to confirm the safety of the duration of the forthcoming phase 2b study, i.e three months.
Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Director Gudmund Korsgard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 26Pila Pharma AB Announces Certification of APIPila Pharma AB announced that the study material to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety studies was outsourced to Almac Group. This production has now been completed as Almac has verified that the final product complies with the specifications and has issued a certificate of analysis. This in turn means that Pila Pharma's development of a new diabetes drug is going according to plan, and that the company can now proceed towards the planned longer preclinical studies that are necessary to be able to carry out a clinical phase 2b study.
